Table 2.
GAP Study Lung Cancer Treatment Secondary Outcomes by Study Arm.
| All patients (n = 180) | GA arm (n = 64) | Usual care arm (n = 116) | P values | |
|---|---|---|---|---|
| Unplanned Hospitalization | 62 (34.4%) | 18 (28.1%) | 44 (37.9%) | 0.19 |
| Dose delay | 55 (30.6%) | 18 (28.1%) | 37 (31.9%) | 0.60 |
| Subsequent dose reduction | 40 (22.2%) | 8 (12.5%) | 32 (27.6%) | 0.02 |
| Early discontinuation of treatment | 37 (20.6%) | 14 (21.9%) | 23 (19.8%) | 0.74 |
| Reduced dose intensity at cycle 1 | 77 (42.8%) | 36 (56.3%) | 41 (35.3%) | <0.01 |
| Overall Survival at 6 months* | 124 (68.9%) | 45 (70.3%) | 79 (68.1%) | 0.76 |
| Overall Survival at 1 year* | 82 (45.6%) | 31 (48.4%) | 51 (44.0%) | 0.56 |
*Censoring is not considered.